MUC-1 aptamer conjugated InP/ZnS quantum dots/nanohydrogel fluorescent composite for mitochondria-mediated apoptosis in MCF-7 cells.
Document Type
Article
Publication Date
1-2021
Publication Title
Materials Science and Engineering: C
Keywords
Breast cancer, Drug delivery systems, MUC-1 aptamer, Nanohydrogel, Quantum dots, Theranostics
ISSN
1873-0191
Volume
118
First Page
111469
Abstract
The combined use of nanohydrogels (NHGs) and quantum dots (QDs) has resulted in the development of a nanoscaled drug delivery system (DDS) with fluorescence imaging potential. NHG-QDs composite loaded with anti-cancer drugs could be applied as an effective theranostics for simultaneous diagnosis and therapy of cancer cells. Here, we report on the synthesis of NHG-QDs nanosystem (NS) conjugated with an amino-modified MUC-1 aptamer (Ap) and loaded with hydrophobic paclitaxel (PTX). To effectively target and eradicate breast cancer MCF-7 cells, the nanocomposite was further loaded with the inhibitor of lactate dehydrogenase (LDH), sodium oxamate (SO) (Ap-NHG-QDs-PTX-SO) to inhibit the conversion of pyruvate to lactate via LDH and disrupting glycolysis. Results obtained from in vitro analysis (MTT assay, apoptosis/necrosis assessment, evaluation of mitochondria targeting, and gene expression profiling) revealed that Ap-NHG-QDs-PTX-SO NS could significantly target and inhibit MCF-7 cells and also induce mitochondria-mediated apoptosis. Collectively, the Ap-NHG-QDs-PTX-SO NS is proposed to serve as a robust theranostics for simultaneous imaging and therapy of breast cancer and other types of solid tumors.
NSUWorks Citation
Ranjbar-Navazi, Zahra; Fathi, Marziyeh; Abdolahinia, Elaheh Dalir; Omidi, Yadollah; and Davaran, Soodabeh, "MUC-1 aptamer conjugated InP/ZnS quantum dots/nanohydrogel fluorescent composite for mitochondria-mediated apoptosis in MCF-7 cells." (2021). HPD Articles. 460.
https://nsuworks.nova.edu/hpd_facarticles/460
ORCID ID
DOI
10.1016/j.msec.2020.111469
Copyright
© 2020 Elsevier B.V.
Comments
This work was supported (Grant No: 95013) by the Research Centre for Pharmaceutical Nanotechnology (RCPN), Tabriz University of Medical Sciences.